99 Percent Of Earth’s Gold Is In Its Core
Sep 02, 2023Researchers extract rare metals from decommissioned wind turbines
Aug 24, 2023EQR signs deal to acquire Spanish tungsten producer Saloro
Aug 19, 2023China Tungsten & Hightech Materials to Set Up Semiconductor Tools Subsidiary
Aug 07, 2023Univar Solutions and Climax Molybdenum Company Strengthen Lubricants Partnership with Exclusive Distribution Agreement into the Latin American Market
Jul 30, 2023Dosing Begins in Phase 2 ReSPECT
Trial Name: A Dual Phase 1/2, Investigator Initiated Study to Determine the Maximum Tolerated Dose, Safety, and Efficacy of 186Rhenium Nanoliposomes (186RNL) in Recurrent Glioma (CTRC# 12-02)
ClinicalTrials.gov Identifier: NCT01906385
Sponsor: Plus Therapeutics
Recruitment Contact: Melissa Moore, PhD, 347-570-3338, [email protected] and Norman LaFrance, MD, (CMO)215-808-0955, [email protected]
Completion Date: January 2025
Trial Name:ClinicalTrials.gov Identifier:Sponsor:Recruitment Contact:Completion Date